The PAAS National® FWA/HIPAA Compliance Program has implemented changes to ensure pharmacies continue to have a robust program in place.
About Trent Thiede, PharmD, MBA
I started working at Shopko, a community pharmacy, in high school. Shopko was a regional chain, and I worked there for 15 years, holding positions as Pharmacy Manager and Regional Pharmacy Supervisor while completing my PharmD from UW-Madison and MBA from UW-Oshkosh. In 2013, I took over Shopko’s Long-Term Care division and helped divest it to KPH HealthCare (aka Kinney Drugs/HealthDirect). I helped grow their business throughout the Midwest, eventually servicing 20,000 beds in under four years.
I have always been involved in pharmacy audits, and hated recoupments, but didn’t see all the opportunities to combat audits the way PAAS does. PAAS is a small, family-orientated company, and I appreciate the opportunity to help independent pharmacies be more successful.
Entries by Trent Thiede, PharmD, MBA
Pharmacy to pharmacy transfers are commonplace in the industry, but much has changed since Lipitor® and Prevacid® were used as currency in a legal drug exchange.
On June 23, 2022 the Drug Enforcement Agency (DEA) created a Guidance Document about the use and posting of guidance documents by the DEA (yes, a guidance document about guidance documents).
Take note – the DEA is coming after pharmacies dispensing illegitimate controlled substance prescriptions. Pharmacists should all be aware of their corresponding responsibility and the need for a legitimate medical purpose when dispensing controlled substance prescriptions.
Community pharmacies have been fed up with PBM antics for a long time. Egregious audits, absurd DIR fees, arduous credentialing requirements, unconscionable contracts; we run out of adjectives before we run out of PBM issues.
Dangers of using Ivermectin to treat or prevent COVID-19. PAAS is seeing more PBM audits on ivermectin prescriptions. Pharmacies should be prepared!
On October 13, 2020, the U.S. Food and Drug Administration issued a statement looking to clarify the intent of the November 2019 label revisions for insulin pens.
Smartphone utilization has, unfortunately, become pervasive with patient interactions. Patients on their phone while trying to consult on new medications, or a patient snapchatting a friend while waiting for their prescription to be filled is all too common.
On April 3, 2020, PAAS National® sent an urgent email alert to all members discussing COVID-19 audit considerations. This email came as a result of our desire to help pharmacies on the frontlines of this pandemic.